论文部分内容阅读
目的探讨端粒酶定量检测联合血清CA125测定在上皮性卵巢癌诊断中的临床意义。方法采用RTQ-PCR法(实时定量端粒重复扩增PCR法)定量检测卵巢上皮性癌组织20例、良性卵巢肿瘤组织5例、12例正常卵巢组织中的端粒酶活性,同时以放免法检测其血清CA125值。结果上皮性卵巢癌Ⅰ～Ⅱ期患者的端粒酶值(197.10±28.20)明显高于Ⅲ～Ⅳ期患者(347.14±60.10)(P<0.05);而与肿瘤组织学分类无关(P>0.05);患者血清CA125水平则与病理类型有关,浆液性囊腺癌组高于黏液性囊腺癌组(P<0.05),而其与临床分期无相关性(P>0.05)。结论端粒酶定量检测联合血清CA125测定有助于卵巢癌的诊断及预后监测。
Objective To investigate the clinical significance of quantitative detection of telomerase combined with serum CA125 in the diagnosis of epithelial ovarian cancer. Methods The telomerase activity in 20 cases of ovarian epithelial carcinoma, 5 cases of benign ovarian tumor and 12 cases of normal ovarian tissue was quantitatively detected by RTQ-PCR (real-time quantitative telomere repeat amplification PCR) Detect the serum CA125 value. Results The telomerase activity in stage Ⅰ ~ Ⅱ patients with epithelial ovarian cancer (197.10 ± 28.20) was significantly higher than that in patients with stage Ⅲ ~ Ⅳ (347.14 ± 60.10) (P <0.05), but not with histological classification (P> 0.05 ). The level of serum CA125 in patients with serous cystadenocarcinoma was higher than that in mucinous cystadenocarcinoma (P <0.05), but no correlation with clinical stage (P> 0.05). Conclusion Quantitative detection of telomerase combined with serum CA125 determination is helpful for the diagnosis and prognosis of ovarian cancer.